Health & Environmental Research Online (HERO)


Print Feedback Export to File
1578502 
Journal Article 
Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden CETP mice 
Bijland, S; Rensen, PCN; Pieterman, EJ; Maas, ACE; van Der Hoorn, JW; van Erk, MJ; Havekes, LM; Willems van Dijk, K; Chang, SC; Ehresman, DJ; Butenhoff, JL; Princen, HMG 
2011 
Toxicological Sciences
ISSN: 1096-6080
EISSN: 1096-0929 
123 
290-303 
English 
uses data from 3927382 TSCA 8(e) substantial risk notice: Sulfonate-based and carboxylic-based fluorochemicals, docket 8EHQ-0598-373 - Results from a mechanistic investigation of the effect of PFBS, PFHS, and PFOS on lipid and lipoprotein metabolism in transgenic mice
Perfluorobutane sulfonate (PFBS), perfluorohexane sulfonate (PFHxS), and perfluorooctane sulfonate (PFOS) are stable perfluoroalkyl sulfonate (PFAS) surfactants, and PFHxS and PFOS are frequently detected in human biomonitoring studies. Some epidemiological studies have shown modest positive correlations of serum PFOS with non-high-density lipoprotein (HDL)-cholesterol (C). This study investigated the mechanism underlying the effect of PFAS surfactants on lipoprotein metabolism. APOE*3-Leiden.CETP mice were fed a Western-type diet with PFBS, PFHxS, or PFOS (30, 6, and 3 mg/kg/day, respectively) for 4-6 weeks. Whereas PFBS modestly reduced only plasma triglycerides (TG), PFHxS and PFOS markedly reduced TG, non-HDL-C, and HDL-C. The decrease in very low-density lipoprotein (VLDL) was caused by enhanced lipoprotein lipase-mediated VLDL-TG clearance and by decreased production of VLDL-TG and VLDL-apolipoprotein B. Reduced HDL production, related to decreased apolipoprotein AI synthesis, resulted in decreased HDL. PFHxS and PFOS increased liver weight and hepatic TG content. Hepatic gene expression profiling data indicated that these effects were the combined result of peroxisome proliferator-activated receptor alpha and pregnane X receptor activation. In conclusion, the potency of PFAS to affect lipoprotein metabolism increased with increasing alkyl chain length. PFHxS and PFOS reduce plasma TG and total cholesterol mainly by impairing lipoprotein production, implying that the reported positive correlations of serum PFOS and non-HDL-C are associative rather than causal. 
cholesterol; lipoprotein; perfluorooctane sulfonate; PPAR alpha; PXR; triglyceride 
• SR Automation
PFAS
• Additional PFAS (formerly XAgency)
     Literature Search November 2019
          Other Sources
               ATSDR
               TEDX
     Screened Studies
          Excluded
               Exclude (TIAB)
• Expanded PFAS SEM (formerly PFAS 430)
     Litsearch: September 2019
          PubMed
          Web of Science
          Other Sources
               PFAS TOX Database
     Screened Studies
          Excluded
               Exclude (TIAB)
     Not prioritized for screening
     Perfluorooctane
• ^Per- and Polyfluoroalkyl Substances (PFAS)
     PFBS (375-73-5)
          Literature Search
               Pubmed
               WOS
     PFHxS (355-46-4)
          Literature search
               Pubmed
               WOS
• PFAS 150
     Literature Search Update December 2020
          PubMed
          WOS
     Literature Search August 2019
          PubMed
          Web of Science
          ToxNet
          Other sources
               Reference list review of included studies
               PFAS TOX Database
     Perfluorobutanesulfonate
     Perfluorobutanesulfonic acid
     Perfluorobutanesulfonyl fluoride
     Perfluorohexanesulfonic acid
     Perfluorooctane
     Perfluorooctanesulfonate
     Perfluorooctanesulfonic acid
• PFBS
          Pubmed
          WOS
          In vivo animal studies
               Liver tox
     Search
          PubMed
          WOS
     Included
          Met PECO Criteria
               Animal
          WOS
     Scopus: April 2021
• PFDA
• PFHxS
     Database searches
          Pubmed
          Toxline
          WOS
          Scopus
          Pelch PFAS SEM
     Inclusion
          TiAb
          Full Text
               Animal Study
• PFNA
• PFOA (335-67-1) and PFOS (1763-23-1)
     Screening Results
          In vivo animal studies
               Liver tox
          In vitro/ex vivo/in silico
• PFOA and PFOS OW MCLG Approaches
     Cited in White Papers
• Yale PFAS Liver study